Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus

[1]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[2]  B. Bierer,et al.  Treatment of chronic graft-versus-host disease with clofazimine. , 1997, Blood.

[3]  R. Stratta.  Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. , 1997, Transplantation proceedings.

[4]  C. Groth.  The European experience with mycophenolate mofetil. European Mycophenolate Mofetil Cooperative Study Group. , 1996, Transplantation proceedings.

[5]  F. Locatelli,et al.  Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. , 1996, Bone marrow transplantation.

[6]  E. Farmer,et al.  Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). , 1996, Bone marrow transplantation.

[7]  M. Pescovitz,et al.  Rescue therapy with mycophenolate mofetil , 1996 .

[8]  C. Groth.  The European experience with mycophenolate mofetil , 1996 .

[9]  Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. , 1996, Transplantation.

[10]  A. Markham,et al.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. , 1996, Drugs.

[11]  J. Niland,et al.  Thalidomide as salvage therapy for chronic graft-versus-host disease. , 1995, Blood.

[12]  H. Dohy,et al.  FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. , 1995, Bone marrow transplantation.

[13]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[14]  G. Phillips,et al.  Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. , 1994, Bone marrow transplantation.

[15]  C. Shanley,et al.  Total lymphoid irradiation for treatment of drug resistant chronic GVHD. , 1993, Bone marrow transplantation.

[16]  D. Jabs,et al.  Thalidomide for the treatment of chronic graft-versus-host disease. , 1992, The New England journal of medicine.

[17]  M. Okuhara,et al.  FK 506: historical perspectives. , 1991, Transplantation proceedings.

[18]  T. Starzl,et al.  FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. , 1991, Transplantation proceedings.

[19]  S. Piantadosi,et al.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. , 1989, Blood.

[20]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[21]  H. Deeg,et al.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. , 1988, Blood.

[22]  M. Okuhara,et al.  Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. , 1987, Transplantation proceedings.